Ott H, Doenicke A, Abress C, Fischl R, Hemmerling K G, Fichte K
Anaesthesist. 1979 Jan;28(1):29-35.
Lormetazepam (0.5, 1, 2, 4, 8 mg)--a new benzodiazepine--was tested versus Pentobarbital (100 mg) under double blind conditions on 240 preoperative inpatients for night-time sedative and side effects after acute oral intake. Results are based on p less than 0.05. Additionally p less than 0.125 in binomial-two-sample-tests was accepted. Lormetazepam shows dose dependent increase in hypnotic effects (e.g. reduction in sleep latency and number of awakenings, increase of total sleep duration), and side effects (e.g. dopiness, dizziness), but no relevant change in vital signs. About 0.5 mg of Lormetazepam are equivalent to 100 mg of Pentobarbital. 2 mg of Lormetazepam seem to be the optimum dose regarding the relation between hypnotic and side effects. In the view of anaesthesists Lormetazepam is preferable to Pentobarbital because of more favorable safety aspects.
氯美扎酮（0.5、1、2、4、8毫克）——一种新型苯二氮䓬类药物——在双盲条件下，与戊巴比妥（100毫克）对240名术前住院患者进行了急性口服后夜间镇静作用及副作用的测试。结果基于p值小于0.05。此外，二项式双样本检验中p值小于0.125也被接受。氯美扎酮显示出催眠作用呈剂量依赖性增加（如睡眠潜伏期缩短、觉醒次数减少、总睡眠时间增加）以及副作用（如嗜睡、头晕），但生命体征无相关变化。约0.5毫克氯美扎酮相当于100毫克戊巴比妥。就催眠作用与副作用的关系而言，2毫克氯美扎酮似乎是最佳剂量。在麻醉师看来，由于安全性更优，氯美扎酮比戊巴比妥更可取。
